Taking flight: Fanshawe College program soars to meet demand for aircraft mechanics
Norton Wolf School of Aviation and Aerospace Technology seen in London, Ont. on May 21, 2025. (Sean Irvine/CTV News London)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
4 hours ago
- CBC
Oyster harvesters in P.E.I. fear overfishing, empty rivers next spring amid MSX concerns
More than 80 of the Island's wild oyster harvesters had to find new places to fish after the MSX parasite forced the shutdown of Bedeque Bay last year. As CBC's Nancy Russell reports, the pressure to find more oysters has meant some rivers are being fished out — and that could mean no catches next spring.
National Post
6 hours ago
- National Post
SFL Missions Inc. Included on Team Awarded Moon Mapping Study Contract by European Space Agency (ESA)
Article content TORONTO — SFL Missions Inc. is a member of the team led by NUVIEW GmbH that has been contracted by the European Space Agency (ESA) to conduct a Pre-Phase A study, within a new scheme for Small Exploration Missions, for the Moonraker lunar mapping mission. The Moonraker satellite will carry a laser scanner to create a detailed elevation map of the Moon's surface. Article content The Moonraker mission will consist of a single orbiter operating in a low-altitude polar orbit around the Moon. The orbiter will host a Light Detection and Ranging (LiDAR) payload to capture highly accurate elevation points of the terrain. These points will be used to generate 3D elevation models that will be relied upon to assess and select future landing sites. Article content Moonraker's LiDAR data will also serve a broader scientific purpose, including scanning permanently shadowed regions for water ice and providing valuable insights into the Moon's geological and interior composition. The Moonraker LiDAR will operator in two modes – one for broad-area scanning of the Moon's polar regions and the other for high-resolution surveys of specific areas of interest. Article content 'As part of the Pre-Phase A contract led by NUVIEW, SFL Missions is supporting the mission concept by contributing to transit trajectory analysis, orbit design, and satellite platform conceptual design for Moonraker,' said Jesse Eyer, NUVIEW Space Missions Architect. 'We're proud to collaborate on advancing this visionary lunar LiDAR initiative.' Article content The mission analysis evaluates possible launch options and trajectories for efficiently entering into lunar orbit, and it studies how the operational orbit parameters impact the spacecraft design and payload data collection. The system design focuses on payload accommodation, spacecraft layout, and sizing of the various subsystem components. In particular, the propulsion system is sized with the appropriate amount of fuel to complete the transit phase and then maintain the operational orbit while counteracting perturbations caused by the Moon's irregular gravity field. Detailed mission and system requirements are also developed to guide future design phases for the project. Article content NUVIEW GmbH of Berlin, Germany, serves as prime contractor for the Pre-Phase A study team, which includes several members in addition to SFL Missions. NUVIEW GmbH is a wholly owned subsidiary of NUVIEW Inc. which is developing the world's first commercial space-based LiDAR constellation for 3D mapping of the Earth. Article content ) Article content SFL Missions Inc. generates bigger returns from smaller, lower cost satellites. Small satellites built by SFL Missions consistently push the performance envelope and disrupt the traditional cost paradigm. We build quality small satellites at low cost that work the first time and enable NewSpace companies to mass produce through our Flex Production program. Satellites are built with advanced power systems, stringent attitude control and high-volume data capacity that are striking relative to the budget. We arrange launches globally and maintain a mission control center accessing ground stations worldwide. The pioneering and barrier-breaking work of SFL Missions is a key enabler to tomorrow's cost-aggressive satellites and constellations. Article content Follow SFL Missions Inc. Article content NUVIEW is a pioneering geospatial technology company headquartered in Orlando, Florida, building the world's first commercial LiDAR satellite constellation. Our mission: to deliver a continuously updated 3D map of the Earth's land surface from space. As the first mover in space-based LiDAR, we're combining cutting-edge satellite, sensor, and software innovations to unlock unprecedented global insights. Article content NUVIEW's integrated data platform empowers users to access and analyze high-resolution elevation models and imagery, including optical, SAR, hyperspectral, and thermal, across a wide range of applications, from climate science and infrastructure planning to agriculture, forestry, and national security. Backed by a team with deep technical expertise and a track record of commercial success, NUVIEW is shaping the future of Earth observation. Article content Article content Article content Article content Article content Contacts Article content NUVIEW Media Contact:
National Post
7 hours ago
- National Post
Neurenati Announces its First Scientific and Clinical Advisory Board Meeting with KOLs to Advance the Development of NEU-001, a Promising Cure for Hirschsprung Disease
Article content MONTRÉAL — Neurenati, an innovative biotechnology company dedicated to developing cutting-edge therapies for unmet medical needs in rare pediatric diseases, is excited to announce the successful convening of its inaugural Scientific and Clinical Advisory Board (SCAB) meeting. This pivotal meeting recently brought together leading pediatric surgeons, gastroenterologists, and industry experts in regulatory affairs and drug development to collaboratively shape a strategic roadmap for advancing NEU-001, a fixed combination of glial cell derived growth factor (GDNF) and butyrate, into clinical stage. Article content The SCAB of Neurenati is composed of Dr Jacob Langer (pediatric surgeon, previously at SickKids Hospital, Toronto), Dr Tomas Wester (pediatric surgeon, Karolinska University Hospital, Stockholm), Dr Anne Dariel (pediatric surgeon, La Timone Hospital, Marseille), Dr Kattayoun Kordy (pediatric gastroenterologist, Founder and CEO Lucien Bio), and Dr Andrew Mulberg (pediatric gastroenterologist and former division deputy director of gastroenterology and inborn errors products, Center for Drug Evaluation and Research, US FDA). Article content The meeting served as a valuable platform for transatlantic dialogue, to share insights on the preclinical prospects of direct benefit, clinical trial design, and regulatory pathways for NEU-001. The diversity of expertise provided Neurenati with meaningful guidance on best clinical practices in both North America and Europe, a deeper understanding of the patient journey, and—most importantly—confirmed the urgent need to advance therapeutic solutions for individuals affected by Hirschsprung disease. 'Hirschsprung disease is an uncommon condition that affects approximately one in 5,000 children. The only effective treatment at this time is a major surgical operation. The innovative work being done by Neurenati could revolutionize the treatment of this disease and could potentially avoid the need for surgery in these tiny children,' said Dr Langer. 'Novel non-operative treatment options for Hirschsprung disease would have a significant impact on future management of these neonates,' confirmed Dr Wester. Article content Looking ahead, Neurenati is committed to leverage a strong collaboration with its scientific and clinical advisory board members as it navigates the path towards IND filing, ensuring that NEU-001 meets the highest standards of safety and efficacy. 'We are thrilled to have gathered such an esteemed group of thought leaders who are passionate about advancing the field of medicine,' said Meriam Kabbaj, DPharm, PhD, Chief Development Officer of Neurenati. 'Their contributions will be instrumental in shaping Neurenati's approach as it prepares for the next phase of its clinical program, with a strong focus on delivering a safe and effective therapy to pediatric patients in need.' Article content Article content Article content Article content Article content Contacts Article content Media Contact:
